Journals / Addicta: The Turkish Journal on Addictions / 2019 / Cilt: 6 - Sayı: 4

Investigation of Independent Variables Affecting Smoking Cessation Success in Early Period Among Adult Patients Using Non-Nicotine Replacement Therapy

Nikotin İçermeyen Tedavi Kullanan Yetişkin Hastalarda Erken Dönem Sigara Bırakma Başarısını Etkileyen Bağımsız Değişkenlerin İncelenmesi

Pages
272–282
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This study, to determine the group wherein the success of smoking cessation was low, provides insights into topics for further research to increase the chance of success.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Choosing the right treatment for tobacco dependence increases the chance of success.
📊
Key Findings & Data:The sample comprised 466 adult patients admitted to our smoking cessation clinic between 2015 and 2019, who started non-NRT treatment, and whose results were known and compatible with the treatment.
💡
Conclusion & Impact:This study, to determine the group wherein the success of smoking cessation was low, provides insights into topics for further research to increase the chance of success.
🔬Design:Research Article
📍Scope:2015 Verileri
⚙️Variables:Domain Parameters

Abstract

Choosing the right treatment for tobacco dependence increases the chance of success. We aimed to determine the independent variables that may predict the success of smoking cessation in patients receiving pharmacotherapy other than nicotine replacement therapy (NRT) and to compare the effectiveness/side effects of treatments. The sample comprised 466 adult patients admitted to our smoking cessation clinic between 2015 and 2019, who started non-NRT treatment, and whose results were known and compatible with the treatment. Logistic regression analysis (Hosmer–Lemeshow test p=0.52) demonstrated the independent variables that reduce the success of smoking cessation: a Fagerström nicotine addiction test score above 8 (p=0.001, OR=1.9, CI=1.29-2.90), negative properties (depressive complaints and reluctance to quit smoking; p=0.009, OR=2.2, CI=1.21-3.99), and a short smoking period (p=0.006, OR=0.97, CI=0.95- 0.99). Varenicline and Bupropion treatments were not superior to each other, and their side effects were similar. This study, to determine the group wherein the success of smoking cessation was low, provides insights into topics for further research to increase the chance of success.

Özet

Tütün bağımlılığında kişiye uygun tedavi seçimi başarı şansını artırmaktadır. Nikotin replasman tedavisi (NRT) dışı farmakoterapi alan hastalarda sigarayı erken dönemde bırakma başarısını öngörebilecek bağımsız değişkenleri belirlemeyi ve tedavilerin etkinliğini/yan etkilerini karşılaştırmayı amaçladık. 2015-2019 yılları arasında sigara bırakma polikliniğimize başvurmuş, NRT dışı tedavi başlanmış olan, sonucu bilinen ve tedaviye uyumlu 466 yetişkin hasta çalışmaya dahil edilmiştir. Lojistik regresyon analizi (Hosmer and lemeshow test p=0,52) sonucunda sigarayı bırakma başarısını azaltan bağımsız değişkenler: Fagerström nikotin bağımlılık testi skorunun 8’in üzerinde olması (p=0,001; OR=1,9; CI=1,29-2,90), olumsuz özelliklerin (depresif yakınmalar ve sigara bırakmada isteksizlik gibi) eşlik etmesi (p=0,009; OR=2,2; CI=1,21-3,99), sigara içilen sürenin kısa olması (p=0,006; OR=0,97; CI= 0,95-0,99) olarak bulunmuştur. Vareniklin ve Bupropion tedavilerinin birbirine üstünlüğünün olmadığı ve yen etkilerinin benzer olduğu görülmüştür. Sigarayı bırakma başarısının düşük olduğu grubun belirlenmesi amacı ile yapılan çalışmamızın, başarı şansının arttırılması için yapılacak çalışmalara ışık tutacak nitelikte olduğunu düşünmekteyiz.

🔖

Cite This Article

SATICI, C., ÖZÜLKÜ, E. (2019). Investigation of Independent Variables Affecting Smoking Cessation Success in Early Period Among Adult Patients Using Non-Nicotine Replacement Therapy. Addicta: The Turkish Journal on Addictions, Cilt: 6 - Sayı: 4, 272–282. https://ajindex.com/articles/126024

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Augustson, E. M., Wanke, K. L., & Rogers, S. (2008). Predictors of sustained smoking cessation: A prospective analysis of chronic smokers from the alpha-tocopherol beta-carotene cancer prevention study. American Journal of Public Health, 98(3), 549-555. https://doi.org/10.2105/ AJPH.2005.084137 [Crossref] Benli, A. R., Erturhan, S., Oruc, M. A., Kalpakci, P., Sunay, D., & Demirel, Y. (2017). A comparison of the efficacy of varenicline and bupropion and an evaluation of the effect of the medications in the context of the smoking cessation programme. Tobacco Induced Diseases, 15, 10. https://doi.org/10.1186/s12971-017-0116-0 [Crossref] Fidan, F., Pala, E., Ünlü, M., Sezer, M., & Kara, Z. (2005). Factors affecting smoking cessation and success rates of the treatment methods used. Kocatepe Medical Journal, 6, 27-34.
  2. Gonzales, D., Rennard, S., Nides, M., Oncken, C., Azoulay, S., Billing, C. B., Watsky, E. J., Gong, J., Williams, K. E., Reeves, K. R., & Varenicline Phase 3 Study Group. (2006). Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained- release bupropion and placebo for smoking cessation: a randomized controlled trial. The Journal of the American Medical Association, 296(1), 47-55. https://doi.org/10.1001/jama.296.1.47 [Crossref] Gourley, S. G., Forbes, A., Marriner, T., Pethica, D., & McNeil, J. J. (1994). Prospective study of factors predicting outcome of transdermal nicotine treatment in smoking cessation. British Medical Journal, 309, 842-846. https://doi.org/10.1136/bmj.309.6958.842 [Crossref] Heatherton, T. F., Kozlowski, L. T., Frecker, R. C., & Fagerstrom, K. O. (1991). The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. British Journal of Addiction, 86(9), 1119-1127. https://doi.org/10.1111/j.1360-0443.1991.tb01879.x [Crossref] Hughes, J. R., Stead, L.F., Hartmann-Boyce, J., Cahill, K., & Lancaster, T. (2014). Antidepressants for smoking cessation. Cochrane Database System Review 8(1), CD000031. https://doi. org/10.1002/14651858.CD000031.pub4 [Crossref] Jorenby, D. E., Hays, J. T., Rigotti, N. A., Azoulay, S., Watsky, E. J., Williams, K. E., Billing, C. B., Gong, J., & Reeves, K. R., Varenicline Phase 3 Study Group. (2006). Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. The Journal of the American Medical Association, 296(1